Literature DB >> 27154156

Is There a Benefit to Prolonging the Interval Between Neoadjuvant Chemoradiation and Esophagectomy in Esophageal Cancer?

Anna Lee1, Andrew T Wong2, David Schwartz2, Joseph P Weiner2, Virginia W Osborn2, David Schreiber2.   

Abstract

BACKGROUND: Evidence suggests that delaying surgical procedures may increase the rate of pathologic complete response (pCR) and that pCR is associated with improved overall survival (OS). In this study, the National Cancer Data Base (NCDB) was analyzed to evaluate this relationship in a large hospital-based registry.
METHODS: We identified patients diagnosed with esophageal adenocarcinoma or squamous cell carcinoma who received neoadjuvant chemoradiation (CRT) followed by esophagectomy from 2003 to 2012. Patients were stratified into quartiles based on the interval between the completion of CRT to operative treatment (≤40 days, 41-50 days, 51-63 days, and ≥64 days), and those with pT0N0M0 were classified as having pCR. Multivariate logistic regression was used to assess the impact of covariates on pCR, and multivariate Cox regression was used to assess their impact on OS.
RESULTS: The study population included 5,393 patients. Increasing the time interval to the surgical procedure was associated with an increased pCR rate (12.3% for ≤40 days to 18.3% for ≥64 days; p < 0.001). On multivariate analysis, a time interval greater than or equal to 51 days was associated with an increased likelihood of pCR (p = 0.009 for 51-63 days; p < 0.001 for ≥64 days), as was an increased radiation dose ≥50 Gy (p = 0.046 for 50-50.4 Gy; p = 0.02 for >50.4 Gy). Increasing the time interval was not associated with an improvement in OS for any quartile on multivariate analysis. In addition, OS was worse for those who underwent operation ≥64 days after completion of radiation therapy (hazard ratio [HR], 1.16; 95% confidence interval [CI], 1.01-1.33; p = 0.03).
CONCLUSIONS: Although increasing the time interval from CRT to surgical intervention was associated with a higher pCR rate, there was no improvement in survival.
Copyright © 2016 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27154156     DOI: 10.1016/j.athoracsur.2016.02.058

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  9 in total

1.  When to resect following neoadjuvant therapy for esophageal cancer-issues and limitations in addressing this decision.

Authors:  Emmanuel Gabriel; Steven N Hochwald
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

Review 2.  Robotic esophagectomy.

Authors:  Brett Broussard; John Evans; Benjamin Wei; Robert Cerfolio
Journal:  J Vis Surg       Date:  2016-08-10

3.  Clinical predictors of pathologically response after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma: long term outcomes of a phase II study.

Authors:  Zihui Tan; Hong Yang; Jing Wen; Kongjia Luo; Qianwen Liu; Yihuai Hu; Lanjun Zhang; Mengzhong Liu; Jingping Yun; Jianhua Fu
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

4.  Optimal Timing to Surgery After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer.

Authors:  Yinkui Wang; Zining Liu; Fei Shan; Xiangji Ying; Yan Zhang; Shuangxi Li; Yongning Jia; Ziyu Li; Jiafu Ji
Journal:  Front Oncol       Date:  2020-12-17       Impact factor: 6.244

5.  Time to surgery in thoracic cancers and prioritization during COVID-19: a systematic review.

Authors:  Scott C Fligor; Savas T Tsikis; Sophie Wang; Ana Sofia Ore; Benjamin G Allar; Ashlyn E Whitlock; Rodrigo Calvillo-Ortiz; Kevin Arndt; Mark P Callery; Sidhu P Gangadharan
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

6.  Impact of the interval between neoadjuvant immunochemotherapy and surgery on surgical-pathological outcomes in non-small cell lung cancer.

Authors:  Jiawei Chen; Hongsheng Deng; Jiaxi He; Zhufeng Wang; Shuben Li
Journal:  Front Oncol       Date:  2022-09-07       Impact factor: 5.738

7.  Timing of surgery after neoadjuvant chemotherapy for gastric cancer: Impact on outcomes.

Authors:  Yi Liu; Ke-Cheng Zhang; Xiao-Hui Huang; Hong-Qing Xi; Yun-He Gao; Wen-Quan Liang; Xin-Xin Wang; Lin Chen
Journal:  World J Gastroenterol       Date:  2018-01-14       Impact factor: 5.742

8.  Association between time interval from neoadjuvant chemoradiotherapy to surgery and complete histological tumor response in esophageal and gastroesophageal junction cancer: a national cohort study.

Authors:  F Klevebro; K Nilsson; M Lindblad; S Ekman; J Johansson; L Lundell; N Ndegwa; J Hedberg; M Nilsson
Journal:  Dis Esophagus       Date:  2020-05-15       Impact factor: 3.429

9.  Timing of Esophagectomy after Neoadjuvant Chemoradiation Therapy Affects the Incidence of Anastomotic Leaks.

Authors:  Simon Roh; Mark D Iannettoni; John Keech; Evgeny V Arshava; Anthony Swatek; Miriam B Zimmerman; Ronald J Weigel; Kalpaj R Parekh
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2019-02-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.